STRIPPOLI, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 14.151
EU - Europa 1.076
AS - Asia 686
OC - Oceania 13
SA - Sud America 5
AF - Africa 4
Totale 15.935
Nazione #
US - Stati Uniti d'America 14.138
CN - Cina 591
SE - Svezia 448
GB - Regno Unito 183
BE - Belgio 92
IT - Italia 67
DE - Germania 58
UA - Ucraina 57
IN - India 45
FI - Finlandia 39
IE - Irlanda 29
FR - Francia 23
IL - Israele 14
NL - Olanda 14
AU - Australia 13
SG - Singapore 9
CA - Canada 8
ES - Italia 7
JP - Giappone 7
CZ - Repubblica Ceca 6
RO - Romania 6
CH - Svizzera 5
HU - Ungheria 5
ME - Montenegro 4
VN - Vietnam 4
BG - Bulgaria 3
MK - Macedonia 3
PA - Panama 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
DK - Danimarca 2
EC - Ecuador 2
HK - Hong Kong 2
HR - Croazia 2
IM - Isola di Man 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
PL - Polonia 2
PT - Portogallo 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
AL - Albania 1
AT - Austria 1
BN - Brunei Darussalam 1
BR - Brasile 1
BS - Bahamas 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 15.935
Città #
Fairfield 2.654
Chandler 1.494
Woodbridge 1.353
Ashburn 1.307
Houston 1.155
Seattle 1.124
Cambridge 1.115
Wilmington 868
Ann Arbor 405
Nyköping 371
Beijing 298
Lawrence 286
Roxbury 281
Des Moines 200
Jacksonville 140
San Diego 113
New York 111
Inglewood 104
Dearborn 94
Brussels 92
Nanjing 61
Falls Church 46
London 45
Washington 42
Pune 33
Dublin 29
Hefei 26
Edinburgh 25
Princeton 24
Kunming 22
Boardman 21
Hebei 18
Brooklyn 17
Guangzhou 17
Jinan 17
Nanchang 17
Hounslow 16
Kilburn 16
Redwood City 16
Bari 15
Paris 15
Changsha 14
Chicago 13
Amsterdam 12
Hadera 11
Jiaxing 11
Shenyang 11
Helsinki 10
Stockholm 9
Prescot 8
Rome 8
San Mateo 8
Zhengzhou 8
New Bedfont 7
San Francisco 7
Tianjin 7
Tokyo 7
Madrid 6
Prague 6
Acton 5
Atlanta 5
Augusta 5
Milan 5
New Delhi 5
Sydney 5
Toronto 5
Wandsworth 5
Budapest 4
Chengdu 4
Dong Ket 4
Norwalk 4
Podgorica 4
Rockhampton 4
Shanghai 4
Wuhan 4
Xian 4
Auburn Hills 3
Belgrade 3
Frankfurt am Main 3
Islington 3
Las Vegas 3
Los Angeles 3
Marseille 3
Messina 3
Miami 3
Panama City 3
Sofia 3
Tel Aviv 3
Zurich 3
Altamura 2
Baotou 2
Bucharest 2
Canberra 2
Chiswick 2
Copenhagen 2
Dalian 2
Dallas 2
Delhi 2
Douglas 2
Dubai 2
Totale 14.403
Nome #
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial 141
A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study 139
Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A systematic review of randomized, controlled trials 131
Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop 127
An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism 110
HMG CoA reductase inhibitors (statins) for kidney transplant recipients 107
Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials 107
Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study 104
Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease 103
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis 96
Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials 92
Addition of the Multidimensional Prognostic Index to the Estimated Glomerular Filtration Rate Improves Prediction of Long-Term All-Cause Mortality in Older Patients with Chronic Kidney Disease 92
Induction and maintenance treatment of proliferative lupus nephritis: A meta-analysis of randomized controlled trials 89
Primary cerebral lymphoma and membranous nephropathy: a still unreported association 88
How to read critically a prognostic cohort study 88
Proteinuria: Does vitamin D treatment improve outcomes in CKD? 88
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease 87
Clinician beliefs and attitudes about home haemodialysis: A multinational interview study 87
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials 87
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials 87
Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-analysis of Observational Studies 86
Antihypertensive agents for preventing diabetic kidney disease 86
null 85
Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease 84
Current structure and organization for renal patient assistance in Italy 83
Sunset for Statins after AURORA? 83
IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice 83
Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet need 82
Aldosterone antagonists for preventing the progression of chronic kidney disease 81
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir 81
Aldosterone antagonists for preventing the progression of chronic kidney disease 81
Fluid intake and all-cause mortality, cardiovascular mortality and kidney function: A population-based longitudinal cohort study 81
null 80
Antiplatelet agents for chronic kidney disease 80
Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials 79
null 79
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis 79
Associations between hemodialysis access type and clinical outcomes: A systematic review 79
Oral disease in adults treated with hemodialysis: prevalence, predictors, and association with mortality and adverse cardiovascular events: the rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study. 78
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials 78
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients 78
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 77
Antihypertensive agents for preventing diabetic kidney disease 76
Quality of reporting of randomization methodology in nephrology trials 76
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy 74
Oral mucosal lesions and risk of all-cause and cardiovascular mortality in people treated with long-term haemodialysis: The ORAL-D multinational cohort study 74
Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients 74
Antiplatelet therapy to prevent hemodialysis vascular access failure: Systematic review and meta-analysis 73
Treatment for peritoneal dialysis-associated peritonitis 73
null 72
KHA-CARI commentary on the KDIGO clinical practice guideline for lipid management in chronic kidney disease 72
Home versus in-centre haemodialysis for end-stage kidney disease 71
Darbepoetin for the anaemia of chronic kidney disease 71
Serum testosterone levels and clinical outcomes in male hemodialysis patients 71
Impact of icodextrin on clinical outcomes in peritoneal dialysis: A systematic review of randomized controlled trials 71
Vitamin D compounds for people with chronic kidney disease not requiring dialysis 70
Correlation of Treatment Time and Ultrafiltration Rate with Serum Albumin and C-Reactive Protein Levels in Patients with End-Stage Kidney Disease Receiving Chronic Maintenance Hemodialysis: A Cross-Sectional Study 70
HMG CoA reductase inhibitors (statins) for dialysis patients 70
Immunosuppressive treatments for immunoglobulin A nephropathy: A meta-analysis of randomized controlled trials 70
Sexual Dysfunction in Women with ESRD Requiring Hemodialysis 69
Proteinuria and Clinical Outcomes in Hypertensive Patients 69
HMG CoA reductase inhibitors (statins) for kidney transplant recipients 69
Vitamin D compounds for people with chronic kidney disease requiring dialysis 68
Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. 68
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients 68
Sevelamer: a promising but unproven drug 68
The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients 68
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 68
Haemoglobin targets: we were wrong, time to move on 67
Antihypertensive agents for primary prevention of diabetic nephropathy 67
How to conduct a randomized trial 67
Biocompatible dialysis fluids for peritoneal dialysis 67
Meta-analysis: Vitamin D compounds in chronic kidney disease 67
The Italian experience of the national registry of renal biopsies 66
Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials 66
Calcimimetics and other simple pharmacological interventions do not work in dialysis: What can we do about it? 66
Non-immunosuppressive treatment for IgA nephropathy 66
The beliefs and expectations of patients and caregivers about home haemodialysis: An interview study 66
null 66
null 65
null 65
Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial 64
null 64
Healthy dietary patterns and risk of mortality and ESRD in CKD: A meta-analysis of cohort studies 64
Thyroid hormones for acute kidney injury 64
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: A systematic review and meta-analysis 64
Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: A cross-sectional analytic study 63
Patients' perspectives on hemodialysis vascular access: A systematic review of qualitative studies 63
null 63
Risk of death following kidney allograft failure: A systematic review and meta-analysis of cohort studies 63
Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease 62
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review 62
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 61
null 61
null 61
null 61
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 61
Treatment for peritoneal dialysis-associated peritonitis 60
A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate 59
Meta-analysis of biochemical and patient-level effects of calcimimetic therapy 59
Totale 7.716
Categoria #
all - tutte 63.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.660


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019183 0 0 0 0 0 0 0 0 0 39 75 69
2019/20206.771 105 33 175 1.242 850 631 762 951 939 525 268 290
2020/20212.908 118 472 152 381 314 153 111 384 78 419 144 182
2021/20222.338 183 341 18 69 111 151 115 84 123 113 172 858
2022/20233.023 429 342 274 292 249 318 27 429 443 22 141 57
2023/2024962 87 181 80 34 120 287 30 125 18 0 0 0
Totale 16.450